Navigation Links
Encorium Reports Second Quarter 2010 Financial Results
Date:8/17/2010

ct," "intend," "believe," "anticipate" and similar expressions.  Those statements involve risks and uncertainties, and actual results could differ materially from those discussed. Factors that could cause or contribute to such differences include, but are not limited to: (i) the risk that we may not have sufficient funds to operate our business; (ii) our success in attracting new business and retaining existing clients and projects; (iii) the size, duration and timing of clinical trials we are currently managing may change unexpectedly; (iv) the termination, delay or cancellation of clinical trials we are currently managing could cause revenues and cash-on-hand to decline unexpectedly; (v) the timing difference between our receipt of contract milestone or scheduled payments and our incurring costs to manage these trials; (vi) outsourcing trends in the pharmaceutical, biotechnology and medical device industries; (vii) the ability to maintain profit margins in a competitive marketplace; (viii) our ability to attract and retain qualified personnel; (ix) the sensitivity of our business to general economic conditions; (x) other economic, competitive, governmental and technological factors affecting our operations, markets, products, services and prices; (xi) announced awards received from existing and potential customers are not definitive until fully negotiated contracts are executed by the parties; (xii) our backlog may not be indicative of future results and may not generate the revenues expected; (xiii) uncertainties regarding the availability of additional capital; (xiv) uncertainties regarding the execution of change orders by our clients for work already performed; and (xv) uncertainties regarding continued listing of our common stock on Nasdaq. You should not place undue reliance on any forward-looking statement. We undertake no obligation to publicly release the result of any revision of these forward-looking statements to reflect events or circumstances af
'/>"/>
SOURCE Encorium Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Encorium Group Signs $6.2 Million of New Contracts Mainly for Vaccines Clinical Trials
2. Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig
3. Encorium Group Provides Update to LOI with Respect to the Sale of its U.S. Business
4. Encorium Re-Appoints Dr. Kai Lindevall as Chief Executive Officer and Appoints Current Director, Shahab Fatheazam, Chairman of the Board
5. Encorium Group, Inc. Appoints Sari Laitinen to Board of Directors
6. Encorium Group, Inc. Acquires Progenitor International Research, a Vaccine Focused Emerging Market CRO
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. Spherix Reports Second Quarter Earnings
9. Tapestry Reports Second Quarter 2007 Results
10. Callisto Reports on Second-Quarter 2007 Milestones
11. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 30, 2014 , Extensively ... cow milk   Cow milk protein allergy (CMPA) is the ... childhood. Until now, it has been managed by eliminating ... been shown that it is possible to help build ... number of children during the first year of life ...
(Date:10/30/2014)... nebulizer is a medical device used for the treatment ... converts liquid medication into mist or aerosol. Thus, the ... patient when inhaled through the mouth or a face ... devices powered by electric current and rechargeable batteries. Factors ... fibrosis and growing number of geriatric population worldwide support ...
(Date:10/30/2014)... Oct. 29, 2014   ViaDerma, Inc. ... bringing new products to market, is committed to ... has developed an innovative, patent-pending dual carrier transdermal ... of pharmaceutical active ingredients to penetrate the skin ... therapy. The transdermal delivery method also overcomes microbial ...
Breaking Medicine Technology:Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3
... 1b study planned for mid 2008 with Phase 2 development ... to begin late in 2008 or in early ... NUVO ) today announced positive results from the Phase 1,proof-of-concept ... offset of anticoagulation after,a single bolus dose with a favorable safety ...
... Erythematosus ... ... (Nasdaq: RIGL ) announced today that its lead product,candidate, R788, ... reported in a recently published,study of the drug candidate. R788 (fostamatinib ...
Cached Medicine Technology:Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172 2Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172 3Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172 4Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies 2Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies 3Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies 4
(Date:10/30/2014)... Hill, South Carolina (PRWEB) October 30, 2014 ... muscle, and should be more vigorously exercised to help ... He recently authored the book ‘Dementia Express: Lose Your ... The book uses counterintuitive reasoning and sometimes conflicting attitudes ... obstacle course for the mind, a reader must decipher ...
(Date:10/30/2014)... -- Scientists who used stem cells to create miniature ... provide a new way to learn more about the ... used human pluripotent stem cells -- which can become ... grow the functional miniature stomachs, to study infection by ... ulcers and stomach cancer. The miniature stomachs offer ...
(Date:10/30/2014)... -- Americans, opinions about the Affordable Care Act are ... Democratic voters are strongly in favor of the ... three-quarters of Democrats want the next Congress to move ... implement the current law, while 44 percent want to ... voters, one-third want the law repealed, and 27 percent ...
(Date:10/29/2014)... Many of the women at first acted surprised. Some insisted ... why they had not used the study products assigned to ... that, as a likely consequence, did not find any of ... , The women were among 127 former VOICE participants who, ... to take part in in-depth interviews and/or focus group discussions ...
(Date:10/28/2014)... (October 27, 2014)—Although oral hormonal therapy is known ... with hormone receptor–positive tumors, about one-half of patients ... study by Columbia University Medical Center (CUMC) researchers ... inhibitors (the most common type of hormone therapy), ... counterparts, increased treatment adherence by 50 percent. , ...
Breaking Medicine News(10 mins):Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2Health News:Voters' Views on Obamacare Split Along Party Lines 2Health News:Women who took part in VOICE speak up about why they didn't use HIV prevention products 2Health News:Women who took part in VOICE speak up about why they didn't use HIV prevention products 3Health News:Generic medications boost adherence to breast cancer therapy 2Health News:Generic medications boost adherence to breast cancer therapy 3
... of times our cells can divide is dictated by telomeres, ... how telomeres keep our chromosomes and by extension, our ... in the fields of both aging and cancer. Now, scientists ... on the structure and function of a crucial domain in ...
... and the UCLA Henry Samueli School of Engineering and ... of Homeland Security,s Science and Technology Directorate to help ... in the field. The UCLA team will work ... on the agency,s PHASER (Physiological Health Assessment System for ...
... Reporter , WEDNESDAY, Sept. 15 (HealthDay News) -- Fresh on the ... study shows that men who have a low prostate-specific antigen (PSA) ... men with a high PSA reading -- 2 nanograms per milliliter ... risk of developing the disease, the researchers added. "If ...
... risk of cardiovascular disease, stroke, high blood pressure, or ... International Journal of Data Mining, Modelling and Management . ... network computer program to analyze patient data and spot ... for an individual. Khanna Nehemiah of the Anna ...
... HealthDay Reporter , TUESDAY Sept. 14 (HealthDay News) -- A ... has sickened a handful of people in North America, with ... officials said Tuesday. But the bacterium -- designated ... of another bacterium that,s been present in the United States ...
... by Indiana University and Columbia University researchers found no ... mental illness or substance abuse problems despite a greater ... illnesses. The study, published online Sept. 15 ... vexing questions about the effectiveness of campaigns designed to ...
Cached Medicine News:Health News:Protein clamps tight to telomeres to help prevent aging...and support cancer 2Health News:Protein clamps tight to telomeres to help prevent aging...and support cancer 3Health News:UCLA selected by Homeland Security to help establish guidelines for firefighter health and safety 2Health News:Men With Low PSA at 60 Might Not Need Further Screening 2Health News:Men With Low PSA at 60 Might Not Need Further Screening 3Health News:Fuzzy thinking could spot heart disease risk 2Health News:New Drug-Resistant 'Superbug' Reaches U.S. Shores 2Health News:New Drug-Resistant 'Superbug' Reaches U.S. Shores 3Health News:Study: Mental illness stigma entrenched in American culture; new strategies needed 2Health News:Study: Mental illness stigma entrenched in American culture; new strategies needed 3
An enzyme linked immunoassay (ELISA) for the detection and semiquantitation of IgG, IgA or IgM anticardiolipin antibodies, as an aid in assessing the risk of thrombosis in individuals with Systemic L...
... Research Grade Microscope Camera from ImagingPlanet ... imaging technology that delivers increased image ... an affordable price. Document, Archive ... 3.3 mega-pixel digital microscope camera designed ...
The ImagingPlanet 70 mm surgical microscope video adapter: Superior optical quality and precise engineering make this 70 mm focal length adapter an excellent decision for use with your Leica surgica...
The ImagingPlanet 55 mm surgical microscope video adapter: superior optical quality and precise engineering make this 55mm focal length adapter an excellent decision for use with your Zeiss surgical ...
Medicine Products: